-continued

#	Example No.	1b (nM)	1a	1a Q30R	2a JFH	2a J6	2b	3a	4a	1a (nM)	1a Q30R (nM)	2a JFH (nM)	2a J6 (t) (nM)	2a J6 (s) (nM)	2b (t) (nM)	2b (s) (nM)	3a (nM)	4a (t) (nM)	4a (s) (nM)	Rat % F
644	MW	0.026	C		C	C	C		C	0.012		0.012	0.020		0.043	0.123			0.011	
645	MX	0.076	C		C	C	C		C	0.036		0.024	0.035		0.070	0.139			0.033	
646	646	0.109	C		C	C	C		C	0.058		0.030	0.042		0.112	0.262			0.034	
648	PJ	0.088	C		C	C	C		C	0.068		0.058	0.136		0.335	0.854			0.056	

The invention claimed is:

1. A compound of the formula:



-continued



2. A pharmaceutical composition comprising a compound of the formula:



and a pharmaceutically acceptable carrier.

3. The pharmaceutical composition of claim **2**, further comprising an inhibitor of hepatitis C virus NS5B polymerase.

4. A method of treating hepatitis C virus in a human patient in need thereof, said method comprising administering to the human patient a pharmaceutical composition comprising a therapeutically effective amount of the compound of the formula:



5. The method of claim 4, further comprising administering an inhibitor of hepatitis C virus NS5B polymerase.

6. The method of claim 5, further comprising administering an interferon or pegylated interferon to the patient.

7. The method of claim 5, further comprising administering ribavirin to the patient.

* * * * *